Wellgistics Health Reports First Quarter 2026 Financials and Provides Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on

Health Reports First Quarter 2026 Financials and Provides

FL - May 19, 2026 (Newswire.com) - Wellgistics Health, Inc. (NASDAQ: WGRX), a health information technology company,

integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx with licensed blockchain-enabled

smart contract technology through PharmacyChain , reported financial results for the first quarter ended March 31, 2026 and provided

a second quarter 2026 business update from its President & Interim-CEO Prashant Patel, RPh.

Company's first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter

growth that is now beginning to reach critical mass in the second quarter," said Prashant Patel, RPh, President & Interim-CEO

Prashant Patel. "We believe the sequential growth in Wellgistics Pharmacy revenue, together with our Kare Pharmtech joint venture,

provides a foundation for continued expansion of our direct-to-patient initiatives. As we work to onboard patient lives available through

the joint venture and prepare for the targeted August 2026 launch of the Health Lives Here initiative with Tollo Health and NFL Alumni

Health, we are also continuing to advance the integration of PharmacyChain functionality with our EinsteinRx pharmacy dispensing

AI hub.As we onboard an increasing percentage of the 200,000+ patient lives through the joint venture, we are preparing to support a

significant ramp up in prescription dispending through our direct-to-consumer initiatives with Tollo Health coming from that planned

August 2026 launch through the partnership with NFL Alumni Health of the "Health Lives Here initiative" that was revealed

at the 2026 NFL Draft in Pittsburgh."

Patel continued, "As we engage with stakeholders in the pharmaceutical distribution space, we believe the GLP-1 market remains

in an early stage of development and that products such as the Forzet medical food product, which is intended to support

the dietary management of muscle loss associated with weight-loss therapies may represent an important adjunct opportunity," We

intend to increasingly focus on the GLP-1 segment and consolidate the capabilities required to provide what we believe to be a seamless

end-to-end user experience that will likely lead to strong customer satisfaction and retention"

believe the cost reduction and operating discipline implemented by management have better aligned the Company's expense structure

with its near-term revenue opportunities,"noted Mr. Patel.

Quarter 2026 Corporate Highlights

Quarter 2026 Corporate Highlights to Date and Upcoming Milestones

discussions with Datavault AI regarding an expansion of the PharmacyChain license to include Health-as-a-Service capabilitiesEstablish

initial HIPAA-compliant data transfer functionality designed to support smart contract-enabled prescription drug transactions through

Wellgistics Pharmacy

Loss from Operations:

Company recorded a net operating loss of $7.742 million in the quarter ended March 30, 2026 compared with a net operating loss of $32.430

million for the quarter ended March 31, 2025. The decrease was largely due to a decrease in general and administrative expenses resulting

from the implementation of cost cutting and other strategic measures by new management. Net operating loss per share for the quarter

ended March 31, 2026 was $0.07 on 104.6 million weighted average shares outstanding compared to the quarter ended March 31, 2025 where

the Company delivered a loss of $0.62 per share on 51.916 million weighted average shares outstanding.

press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any

securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Health, Inc.

Health (NASDAQ:WGRX), is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial

intelligence platform EinsteinRx into its blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription

drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution,

digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence

support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.

press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy

revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August

2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding

GLP-1 related opportunities, the integration of PharmacyChain functionality with EinsteinRx , the potential expansion of

the Datavault AI PharmacyChain license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant

data transfer functionality, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities

and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees

of future performance. These statements may be identified by words such as "anticipate," "believe," "expect,"

"intend," "plan," "target," "may," "will," "would," "could,"

"should," "seek," "estimate," "project," "potential," "continue"

and similar expressions.

statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed

or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second

quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate

Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain functionality and other strategic initiatives; the Company's ability

to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize

and scale EinsteinRx and PharmacyChain -enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare,

FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings;

the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions

in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's

ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's

filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most

recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company

undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or

otherwise, except as required by law.

Media & Investor Contact

Media: media@wellgisticshealth.com

Investor Relations: IR@wellgisticshealth.com

Wellgistics Health, Inc.